The importance of maternal insulin resistance throughout pregnancy on neonatal adiposity

Lima, Rodrigo A; Desoye, Gernot; Simmons, David; Devlieger, Roland; Galjaard, Sander; Corcoy, Rosa; Adelantado, Juan M; Dunne, Fidelma; Harreiter, Jürgen; Kautzky-Willer, Alexandra; Damm, Peter; Mathiesen, Elisabeth R; Jensen, Dorte M; Andersen, Lise-Lotte T; Tanvig, Mette; Lapolla, Annunziata; Dalfra, Maria G; Bertolotto, Alessandra; Manta, Urszula; Wender-Ozegowska, Ewa; Zawiejska, Agnieszka; Hill, David J; Snoek, Frank J; Jelsma, Judith G M; van Poppel, Mireille

Published in:
Paediatric and Perinatal Epidemiology (Print)

DOI:
10.1111/ppe.12682

Publication date:
2021

Document version
Final published version

Document license
CC BY

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying this open access version.
The importance of maternal insulin resistance throughout pregnancy on neonatal adiposity

Rodrigo A. Lima1 | Gernot Desoye2 | David Simmons3,4 | Roland Devlieger5 | Sander Galjaard5,6 | Rosa Corcò7,8 | Juan M. Adelantado7,8 | Fidelma Dunne9 | Jürgen Harreiter10 | Alexandra Kautzy-Willer10 | Peter Damm11 | Elisabeth R. Mathiesen11 | Dorte M. Jensen12,13 | Lise-Lotte T. Andersen12,14 | Mette Tanvig12,14 | Annunziata Lapolla15 | Maria G. Dalfra15 | Alessandra Bertolotto16 | Urszula Manta17 | Ewa Wender-Ozegowska17 | Agnieszka Zawiejska17 | David J. Hill18 | Frank J. Snoek19 | Judith G. M. Jelsma20 | Mireille van Poppel1

1Institution of Sport Science, University of Graz, Graz, Austria
2Department of Obstetrics and Gynecology, Medizinische Universitaet Graz, Graz, Austria
3Western Sydney University, Campbelltown, New South Wales, Australia
4The Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
5KU Leuven Department of Development and Regeneration: Pregnancy, Fetus and Neonate, Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium
6Division of Obstetrics and Prenatal Medicine, Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
7Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
8CIBER Bioengineering, Biomaterials and Nanotechnology, Instituto de Salud Carlos III, Zaragoza, Spain
9Galway Diabetes Research Centre and College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland
10Gender Medicine Unit, Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
11Departments of Endocrinology and Obstetrics, Faculty of Health and Medical Sciences, Center for Pregnant Women with Diabetes, Rigshospitalet, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
12Department of Gynecology and Obstetrics, Odense University Hospital, University of Southern Denmark, Odense, Denmark
13Department of Clinical Research, Faculty of Health Sciences, Steno Diabetes Center Odense, Odense University Hospital, University of Southern Denmark, Odense, Denmark
14Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
15Università Degli Studi di Padova, Padua, Italy
16Azienda Ospedaliero Universitaria – Pisa, Pisa, Italy
17Department of Reproduction, Poznan University of Medical Sciences, Poznan, Poland
18Recherche en Santé Lawson SA, Bronschhofen, Switzerland
19Department of Medical Psychology, Amsterdam Public Health research institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
20Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Paediatric and Perinatal Epidemiology published by John Wiley & Sons Ltd
Correspondence
Rodrigo A. Lima, Institute of Sport Science, University of Graz, Graz, Austria. Email: rodrigoantlima@gmail.com

Funding information
This study was funded by the European Union 7th Framework (FP7/2007–2013) under Grant Agreement no. 242187. Additional funding was provided by the Netherlands Organisation for Health Research and Development (ZonMW) (grant 200310013), in the Netherlands. In Poland, additional funding was obtained from Polish Ministry of Science (grants 2203/7, PR/2011/2). In Denmark, additional funding was provided by Odense University Free Research Fund. In Spain, additional funding was provided by CAIBER 1527-B-226. The study sponsors were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

1 | BACKGROUND

Maternal obesity is associated with neonatal1-4 and childhood adiposity, and childhood obesity2,5 is not only associated with a higher chance of obesity, but also premature death and disability in adulthood.2 While maternal insulin resistance and fasting glucose have a positive association with neonatal adiposity,6-13 the role of maternal triglycerides and non-esterified fatty acids on neonatal adiposity remains controversial.6-8,11 It is unclear whether such associations are causal, in the causal pathway or a consequence of the metabolic pathways involved.

Shapiro et al6 reported that HOMA-IR, glucose, but not triglycerides and non-esterified fatty acids at 24-32 weeks of gestation mediated the association between maternal pre-pregnancy body mass index (BMI) and neonatal adiposity. Although this study6 provided relevant insights regarding the possible underlying mechanisms in the relationship between maternal metabolic profile and neonatal adiposity, some aspects still require further evaluation. First, it is crucial that the entire pregnancy period is taken into account. Fetal development depends on the maternal metabolic profile throughout the whole pregnancy period,6-13 illustrated by the fact that obese women or women who develop gestational diabetes have larger fetuses already by 20 weeks of gestation.14,15 Second, there is evidence that neonatal girls might be more insulin resistant than boys,16,17 and mechanisms underlying the relationship between maternal metabolism and neonatal adiposity might differ depending on the neonatal sex.18

The aim of this investigation was to evaluate the direct and indirect associations between insulin resistance during pregnancy and neonatal adiposity, as measured by sum of skinfolds. In addition, the direct and indirect associations between fasting glucose, triglycerides, non-esterified fatty acids, and neonatal adiposity were also assessed. This is a novel approach because it assesses the complexity of the relationships among different maternal health parameters with neonatal adiposity, little is known regarding the complexity of the relationships among different maternal health parameters throughout pregnancy and its impact on neonatal adiposity.

Abstract

Background: Although previous studies evaluated the association of maternal health parameters with neonatal adiposity, little is known regarding the complexity of the relationships among different maternal health parameters throughout pregnancy and its impact on neonatal adiposity.

Objectives: To evaluate the direct and indirect associations between maternal insulin resistance during pregnancy, in women with obesity, and neonatal adiposity. In addition, associations between maternal fasting glucose, triglycerides (TG), non-esterified fatty acids (NEFA), and neonatal adiposity were also assessed.

Methods: This is a longitudinal, secondary analysis of the DALI study, an international project conducted in nine European countries with pregnant women with obesity. Maternal insulin resistance (HOMA-IR), fasting glucose, TG, and NEFA were measured three times during pregnancy (<20, 24-28, and 35-37 weeks of gestation). Offspring neonatal adiposity was estimated by the sum of four skinfolds. Structural equation modelling was conducted to evaluate the direct and indirect relationships among the variables of interest.

Results: Data on 657 mother-infant pairs (50.7% boys) were analysed. Neonatal boys exhibited lower mean sum of skinfolds compared to girls (20.3 mm, 95% CI 19.7, 21.0 vs 21.5 mm, 95% CI 20.8, 22.2). In boys, maternal HOMA-IR at <20 weeks was directly associated with neonatal adiposity (β = 0.35 mm, 95% CI 0.01, 0.70). In girls, maternal HOMA-IR at 24-28 weeks was only indirectly associated with neonatal adiposity, which implies that this association was mediated via maternal HOMA-IR, glucose, triglycerides, and NEFA during pregnancy (β = 0.26 mm, 95% CI 0.08, 0.44).

Conclusions: The timing of the role of maternal insulin resistance on neonatal adiposity depends on fetal sex. Although the association was time-dependent, maternal insulin resistance was associated with neonatal adiposity in both sexes.

Keywords
endocrinology, gynaecology, insulin, lipid metabolism, obesity
2 | METHODS

2.1 | Design and participants

This is a longitudinal, secondary analysis of the DALI study which was a multicentre parallel randomised trial conducted in nine European countries (Austria, Belgium, Denmark, Ireland, Italy, Netherlands, Poland, Spain, and United Kingdom) during 2012-2015. Pregnant women with a pre-pregnancy body mass index (BMI) of ≥29 kg/m², before 20 weeks of gestation, with a singleton pregnancy, and aged ≥18 years were invited to participate. Exclusions included diagnosis with early gestational diabetes mellitus (GDM), pre-existing diabetes, and chronic medical conditions. The study was prospectively registered as a randomised controlled trial (RCT) on 21 November 2011 (ISRCTN70595832).

2.2 | Randomisation, masking, and interventions

Using a computerised random number generator, women were randomised to one of the following groups, pre-stratified for site: (a) healthy eating; (b) physical activity; (c) healthy eating + physical activity; (d) healthy eating + physical activity + vitamin D; (e) healthy eating + physical activity + placebo; (f) vitamin D; (g) placebo; and (h) control. Staff involved with measurements, but not participants, were blinded to the intervention. Since methodology has been extensively described elsewhere, only variables of interest will be detailed in this manuscript.

2.3 | Measurements

2.3.1 | Neonatal adiposity

Triceps, subscapular, supra-iliac, and quadriceps skinfolds were measured with a Harpenden skinfold calliper, and values summed. Each skinfold measurement was repeated once, and if a difference of more than 0.2 mm was registered, a third measurement was performed and the average of the three was taken. Time between birth and measurements was registered in hours—neonatal age at the measurement.

2.3.2 | Maternal measurements

Maternal height was determined at baseline with a stadiometer (SECA 206; SECA, Birmingham United Kingdom). Women were weighed on calibrated electronic scales (SECA 888 and 877) at baseline (<20 weeks), 24-28 weeks, and at 35-37 weeks of gestation. Body mass index (BMI) was calculated as weight in kg divided by the square of height in metres.

After fasting for 10 hours, blood was collected in three different periods during pregnancy (<20, 24-28, and 35-37 weeks of gestation). The procedures were identical in all pregnancy periods. All the samples were centrifuged and separated aliquots (1000 or 250 μL) placed in microrack tubes and stored at −20 or −80°C in the central trial laboratory, prior to analysis, in Graz, Austria. The maternal plasma concentrations of fasting glucose, triglycerides, and non-esterified fatty acids were quantified. For insulin and leptin, commercially available enzyme-linked immunosorbent assays (ELISAs) were used. Insulin resistance was derived from homeostasis model assessment (HOMA-IR).

2.3.3 | Covariates

Information on possible covariates was collected in the baseline questionnaire or from medical files: intervention groups, maternal age, gestational age during pregnancy (<20, 24-28 and 35-37 weeks), maternal ethnicity (European descent and non-European descent), maternal education (low [high school], medium [completed high school] and high [higher education]), smoking status at 35-37 weeks of gestation (yes and no), gestational age at birth (weeks of gestation), and neonatal age (hours).
2.4 | Statistical analyses

Prevalence, means, standard deviations (SD), medians, and interquartile ranges (IQR) were used to describe the sample. Descriptive mean differences are presented with respective 95% confidence intervals.

Structural equation modelling was performed to evaluate the direct and indirect associations among maternal HOMA index, glucose, triglycerides, non-esterified fatty acids, and neonatal sum of skinfolds. Direct association refers to the association between two variables, whereas indirect association refers to the association between two variables that is mediated via a third variable. All the standard errors in the analyses were adjusted for the cluster structure of the data (individuals nested within site of recruitment). Table 1 describes the role of each variable in the diagram in detail, including the variables of interest and the adjustments. We have more than 80% statistical power to detect associations with small effect sizes ($f^2 = 0.06$) considering the number of neonatal boys ($n = 333$) and girls ($n = 324$) evaluated, accounting for the number of exposures and confounding variables in our analysis. All analyses were performed in STATA version 15 for windows (StataCorp LP).

2.5 | Missing data

We used the maximum likelihood for missing values method, which does not exclude a participant in the analysis because of a missing value in one of the variables. Thus, we avoided selection bias in our analysis. Therefore, all the 657 neonates and their mothers in the study were included in the main analysis.

2.6 | Ethics approval

We obtained the local ethics committee approvals in all the nine countries, in which the study was conducted. Moreover, written informed consent of all women was acquired.

3 | RESULTS

In total, 657 neonates (50.7% boys) and their mothers with obesity were included in the study. On average, the mothers were 32.0 (±5.4) years of age. Median gestational age at delivery was 39.7 (IQR: 38.7; 40.9) weeks of gestation. Most mothers perceived themselves as European descent (86.4%). Among the mothers, 55.9% reported a high educational level and 31.8% a medium educational level. Median neonatal age at measurement was 5.0 (IQR: 2.0; 24.0) hours after birth. Boys exhibited a lower sum of skinfolds (mean sum of skinfolds 20.3 mm, 95% CI 19.7, 21.0) compared to girls (mean sum of skinfolds 21.5 mm, 95% CI 20.8, 22.2). Table 2 presents descriptive data on the mothers’ metabolic variables at <20 weeks of gestation according to the sex of the fetus.

3.1 | Maternal insulin resistance in relation to neonatal adiposity

In boys, maternal HOMA-IR at <20 weeks of gestation was directly associated with neonatal sum of skinfolds ($\beta = 0.35$ mm, 95% CI 0.01, 0.70). No other associations of maternal HOMA-IR with neonatal sum of skinfolds in boys were found (see Table 3). In girls, maternal HOMA-IR was not directly associated with neonatal sum of skinfolds at any time during pregnancy. However, maternal HOMA-IR at 24-28 weeks of gestation was indirectly associated with neonatal sum of skinfolds ($\beta = 0.26$ mm, 95% CI 0.08, 0.44).

Figure 1 illustrates the indirect association of maternal HOMA-IR at 24-28 weeks of gestation with neonatal sum of skinfolds only in girls because we did not observe an indirect association between maternal HOMA-IR and neonatal sum of skinfolds in boys. Note that not all the arrows were drawn for clarity. We only drew the most relevant arrows related to the primary and secondary outcomes of the present study. For more details regarding all the relationships tested in our diagram, see Table 1. The indirect association of maternal HOMA-IR at 24-28 weeks of gestation with neonatal sum of skinfolds indicates that a higher maternal HOMA-IR at 24-28 weeks initiates a chain of relationships through maternal fasting glucose, triglycerides, and NEFA at 24-28 weeks and HOMA-IR, fasting glucose, triglycerides, and NEFA at 35-37 weeks that culminates in a higher neonatal sum of skinfolds (Figure 1). The overall indirect association between maternal HOMA-IR at 24-28 weeks and neonatal sum of skinfolds was 0.26 mm (95% CI 0.06, 0.36), and the indirect association between maternal HOMA-IR at 24-28 weeks and neonatal sum of skinfolds only via maternal fasting glucose at 24-28 weeks was 0.21 mm (95% CI 0.06, 0.36), indicating that 81.0% of the indirect relationship between maternal HOMA-IR at 24-28 weeks and neonatal sum of skinfolds was mediated via fasting glucose at 24-28 weeks.

3.2 | Maternal fasting glucose, triglycerides, and non-esterified fatty acids in relation to neonatal adiposity

In boys, maternal triglycerides at <20 weeks were indirectly and negatively associated with neonatal sum of skinfolds ($\beta = −0.49$ mm, 95% CI −0.97, −0.01). Moreover, triglycerides at 24-28 weeks of gestation were directly and negatively associated with neonatal sum of skinfolds only via maternal fasting glucose at 24-28 weeks was −1.39 mm, 95% CI −2.58, −0.21). Maternal fasting glucose and NEFA were not associated with neonatal sum of skinfolds in boys at any time during pregnancy (Table 4).

In girls, maternal fasting glucose at <20 weeks was inversely and directly associated with neonatal sum of skinfolds ($\beta = −2.52$ mm, 95% CI −4.86, −0.19), whereas the indirect association was positive ($\beta = 1.82$ mm, 95% CI 0.85, 2.79). Thus, the total association between maternal fasting glucose at <20 weeks and neonatal sum of skinfolds was not significant ($\beta = −0.70$ 95% CI −2.94, 1.54).
Maternal fasting glucose at 24-28 weeks was directly and positively associated with neonatal sum of skinfolds ($\beta = 2.51$ mm, 95% CI 0.80, 4.23). Maternal NEFA at 35-37 weeks were directly and negatively associated with neonatal sum of skinfolds ($\beta = -3.26$ mm, 95% CI −5.91, −0.61). Maternal triglycerides were not associated with neonatal sum of skinfolds in girls at any time during pregnancy (Table 4).

### 3.3 | Comment

#### 3.3.1 | Principal findings

The primary aim of this investigation was to evaluate the potential pathophysiological pathways underlying the association of maternal insulin resistance with neonatal adiposity in pregnant women.
with obesity. Since this is a longitudinal study, it is not possible to infer causality in our conclusions. Our results showed that the association between maternal insulin resistance and neonatal adiposity differed depending on the infant sex. While adiposity in boys was associated directly with maternal insulin resistance in the beginning of pregnancy, adiposity in girls was associated with maternal insulin resistance at 24-28 weeks of gestation via a chain of relationships through fasting glucose, triglycerides, and free fatty acids.

### 3.3.2 | Strengths of the study

Strengths of our study are that we have measures of maternal metabolic parameters at three time points in pregnancy, enabling us to look at longitudinal associations. Data were collected in nine European countries, increasing the external validity of our findings. Importantly, the mechanistic path analysis adds substantial insights on how some of the metabolic parameters during pregnancy in women with obesity could affect neonatal adiposity, although we cannot assert on causality and our model should be tested in clinical trials.

### 3.3.3 | Limitations of the data

Our findings should be interpreted with caution, since women were exposed to different interventions that could influence our results. However, the analyses were adjusted for the intervention component. Another limitation is the lack of normal or overweight women in the study; thus, we can only generalise our findings to Caucasian obese women. However, the prevalence and the increasing rate of obesity in women in reproductive age are alarming and so the complication related to obesity during pregnancy. Furthermore, more direct measures of neonatal adiposity would have been preferred, such as from air displacement plethysmography, although sum of skinfolds provide valid estimates of adiposity.

<table>
<thead>
<tr>
<th>Maternal variables</th>
<th>&lt;20 wk of gestation</th>
<th>24-28 wk</th>
<th>35-37 wk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Boys</td>
<td>Mean (95% CI)</td>
<td>Girls</td>
</tr>
<tr>
<td>HOMA-IR (µU/mL)</td>
<td>327</td>
<td>3.0 (2.7, 3.4)</td>
<td>315</td>
</tr>
<tr>
<td>Fasting Glucose (mmol/L)</td>
<td>331</td>
<td>4.6 (4.6, 4.6)</td>
<td>320</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>320</td>
<td>1.3 (1.3, 1.4)</td>
<td>307</td>
</tr>
<tr>
<td>Non-esterified fatty acids (mmol/L)</td>
<td>320</td>
<td>0.6 (0.6, 0.7)</td>
<td>307</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>333</td>
<td>34.4 (34.0, 34.8)</td>
<td>324</td>
</tr>
</tbody>
</table>

**TABLE 2** Mean and 95% confidence intervals of the mothers’ anthropometric and metabolic variables at <20 wk of gestation according to the sex of the fetus

<table>
<thead>
<tr>
<th>Exposures</th>
<th>Neonatal sex</th>
<th>Neonatal sum of skinfolds (mm)</th>
<th>Direct association</th>
<th>Indirect association</th>
<th>Total association</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOMA-IR</td>
<td>Boys</td>
<td>0.35 (0.01, 0.70)</td>
<td>−0.02 (−0.17, 0.14)</td>
<td>0.34 (0.01, 0.66)</td>
<td></td>
</tr>
<tr>
<td>at &lt; 20 wk</td>
<td>Girls</td>
<td>0.20 (−0.02, 0.43)</td>
<td>−0.05 (−0.18, 0.08)</td>
<td>0.15 (−0.08, 0.38)</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>Boys</td>
<td>−0.43 (−0.88, 0.03)</td>
<td>0.09 (−0.05, 0.22)</td>
<td>−0.34 (−0.83, 0.15)</td>
<td></td>
</tr>
<tr>
<td>at 24-28 wk</td>
<td>Girls</td>
<td>0.01 (−0.41, 0.41)</td>
<td>0.26 (0.08, 0.44)</td>
<td>0.26 (−0.09, 0.61)</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>Boys</td>
<td>0.05 (−0.12, 0.22)</td>
<td>0.05 (−0.03, 0.14)</td>
<td>0.10 (−0.11, 0.31)</td>
<td></td>
</tr>
<tr>
<td>at 35-37 wk</td>
<td>Girls</td>
<td>−0.01 (−0.12, 0.10)</td>
<td>0.07 (−0.01, 0.15)</td>
<td>0.06 (−0.05, 0.17)</td>
<td></td>
</tr>
</tbody>
</table>

Note: Indirect association refers to the association between the exposure (maternal HOMA-IR at different periods during pregnancy) and the outcome (neonatal sum of skinfolds) which is mediated by all the variables in the pathway (see Table 1 for detailed description).

**TABLE 3** Path coefficients of the direct, indirect, and total association between maternal HOMA-IR and neonatal sum of skinfolds

### 3.3.4 | Interpretation

Regarding the pathophysiological pathways on the relationship between maternal metabolism and neonatal adiposity, Shapiro et al. observed that 21.0% of the association between maternal pre-pregnancy BMI and neonatal adiposity was mediated by HOMA-IR and fasting glucose levels, but not by triglycerides or non-esterified fatty acids. This is partly in line with our results, although Shapiro et al. included pregnant women with and without obesity whereas we only included pregnant women with obesity. We observed that fasting glucose mediated 81.0% of the association between maternal HOMA-IR and neonatal adiposity, but only in girls.
FIGURE 1  Paths in the association between maternal HOMA-IR at 24-28 wk and neonatal sum of skinfolds in girls. Fasting glucose, triglycerides, and non-esterified fatty acids (NEFA) at 24-28 wk were directly associated with fasting glucose, triglycerides, and NEFA at 35-37 wk, respectively. SSF refers to the neonatal sum of skinfolds (mm). Solid lines refer to direct relationships; dashed lines refer to indirect relationships.

TABLE 4  Path coefficients of the direct, indirect, and total association between maternal fasting glucose, triglycerides, non-esterified fatty acids, and neonatal sum of skinfolds

<table>
<thead>
<tr>
<th>Exposures, in mmol/l</th>
<th>Gestational age during pregnancy</th>
<th>Boys</th>
<th>Total association</th>
<th>Direct association</th>
<th>Indirect association</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>β (95% CI)</td>
<td>β (95% CI)</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>&lt;20 wk</td>
<td>0.44 (−1.10, 1.98)</td>
<td>−0.31 (−2.06, 1.43)</td>
<td>0.75 (−0.60, 2.11)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24-28 wk</td>
<td>0.68 (−1.36, 2.72)</td>
<td>0.09 (−1.86, 2.04)</td>
<td>0.59 (−0.38, 1.57)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35-37 wk</td>
<td>1.22 (−0.75, 3.19)</td>
<td>1.22 (−0.75, 3.19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>&lt;20 wk</td>
<td>1.12 (−0.59, 2.84)</td>
<td>1.61 (−0.31, 3.54)</td>
<td>−0.49 (−0.97, −0.01)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24-28 wk</td>
<td>−0.87 (−1.58, −0.15)</td>
<td>−1.39 (−2.58, −0.21)</td>
<td>0.53 (−0.23, 1.28)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35-37 wk</td>
<td>0.78 (−0.26, 1.81)</td>
<td>0.78 (−0.26, 1.81)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-esterified fatty acids</td>
<td>&lt;20 wk</td>
<td>1.01 (−1.27, 3.28)</td>
<td>1.19 (−0.33, 2.71)</td>
<td>−0.18 (−1.92, 1.55)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24-28 wk</td>
<td>−1.58 (−5.90, 2.75)</td>
<td>−1.77 (−6.17, 2.62)</td>
<td>0.20 (−0.38, 0.77)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35-37 wk</td>
<td>1.32 (−2.56, 5.20)</td>
<td>1.32 (−2.56, 5.20)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposures, in mmol/l</th>
<th>Gestational age during pregnancy</th>
<th>Girls</th>
<th>Total association</th>
<th>Direct association</th>
<th>Indirect association</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>β (95% CI)</td>
<td>β (95% CI)</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>&lt;20 wk</td>
<td>−0.70 (−2.94, 1.54)</td>
<td>−2.52 (−4.86, −0.19)</td>
<td>1.82 (0.85, 2.79)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24-28 wk</td>
<td>2.84 (1.38, 4.30)</td>
<td>2.51 (0.80, 4.23)</td>
<td>0.33 (−0.24, 0.90)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35-37 wk</td>
<td>0.71 (−0.49, 1.91)</td>
<td>0.71 (−0.49, 1.91)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>&lt;20 wk</td>
<td>0.80 (−0.30, 1.90)</td>
<td>0.43 (−1.31, 2.17)</td>
<td>0.37 (−0.99, 1.72)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24-28 wk</td>
<td>0.01 (−1.47, 1.50)</td>
<td>−0.64 (−2.46, 1.19)</td>
<td>0.65 (−0.44, 1.74)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35-37 wk</td>
<td>0.93 (−0.63, 2.49)</td>
<td>0.93 (−0.63, 2.49)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-esterified fatty acids</td>
<td>&lt;20 wk</td>
<td>1.73 (−0.88, 4.34)</td>
<td>1.47 (−0.38, 3.31)</td>
<td>0.26 (−1.07, 1.60)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24-28 wk</td>
<td>2.23 (−1.92, 6.38)</td>
<td>3.02 (−0.99, 7.03)</td>
<td>−0.79 (−1.74, 0.16)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>35-37 wk</td>
<td>−3.26 (−5.91, −0.61)</td>
<td>−3.26 (−5.91, −0.61)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Indirect association refers to the association between the exposure and the outcome (neonatal sum of skinfolds) which is mediated by all the variables in the pathway (see Table 1 for detailed description). The empty cells on the indirect relationships between fasting glucose, triglycerides, non-esterified fatty acids at 35-37 wk of gestation and neonatal sum of skinfolds are due to the lack of possible indirect relationships to be estimated (there are no intermediate variable between these exposures and the outcome).
The direct association between maternal glucose and neonatal adiposity is well established in the literature. Results from the Healthy Heart Study, the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study demonstrated the importance of maternal glucose levels for neonatal adiposity. In our sample only including pregnant women with obesity, we did not observe any relationship between maternal fasting glucose and neonatal adiposity in boys. In girls, maternal fasting glucose at 24-28 weeks was associated with neonatal adiposity. No relationship was observed between maternal fasting glucose at <20 weeks or at 35-37 weeks and neonatal adiposity. We encourage future investigations to evaluate this matter in more depth, with assessment of maternal glucose levels at multiple time points during pregnancy.

The importance of triglycerides and non-esterified fatty acids levels during pregnancy on neonatal adiposity is not well established. When associations are found they are usually positive. In our sample with pregnant women with obesity, maternal triglycerides were negatively associated with neonatal adiposity in boys at <20 weeks (indirectly) and at 24-28 weeks (directly). In girls, maternal non-esterified fatty acids at 35-37 weeks showed a negative association with neonatal adiposity. Pregnant women with obesity from DALI exposed to motivational sessions on healthy eating presented higher levels of NEFA, and higher levels of NEFA were also found in the cord blood of the offspring when compared to controls. In addition, maternal diet has been shown to influence triglyceride and free fatty acid levels, even after a period of fasting. Whether this influenced the association between lipids and neonatal adiposity is unknown. However, there seems to be a complex interaction between maternal glycaemia and lipids in their influence on fetal growth, since maternal lipids were only associated with fetal growth in women with hyperglycaemia but not in those with normal glycaemia. Whether this is due to differences in insulin resistance and therefore maternal lipolysis needs further study.

Sex differences in the associations between maternal metabolism and neonatal adiposity have been reported previously, but are inconsistent. Inconsistencies might be due to study population (ie women with obesity versus with normal weight, with normal glycaemia versus with hyperglycaemia) or due to differences in the timing in pregnancy. Theoretically, male and female fetuses seem to experience different growth strategies in utero. It is not well established yet, but male embryos tend to have more rapid cell divisions compared to females, generating a more rapid growth. This higher growth rate might explain the higher response to changes in nutrient supply reported in male fetuses. These different growth strategies might result in differences in nutritional needs, at different times in pregnancy and our findings support this concept. However, more systematic assessment of sex differences in the relationship of maternal metabolic parameters with neonatal adiposity is needed.

We evaluated the pathophysiological pathway from maternal insulin resistance, through maternal glucose, triglycerides, and non-esterified fatty acids to neonatal adiposity in pregnant women with obesity. It indicates again the relevance of the early pregnancy period for neonatal outcomes in boys and in the middle of pregnancy for girls. Although our model explained most of the pathophysiological pathways from insulin resistance to neonatal adiposity in girls, the pathways in boys were still uncertain. A next step would be to investigate the associations of maternal metabolism with cord blood parameters, to confirm the Pedersen-Freinkel hypothesis that maternal glucose and lipids increase fetal insulin levels and thereby increase fetal fat accretion.

4 | CONCLUSIONS

Maternal insulin resistance in women with obesity was associated with adiposity in neonates. More specifically, higher insulin resistance in the beginning of pregnancy was related to higher adiposity in boys, whereas this association in girls was observed with insulin resistance in the middle of the pregnancy period. Obstetricians, midwives, and health professionals should be aware of the deleterious impact of maternal insulin resistance on the offspring health and support pregnant women with life style changes (nutrition and physical activity) which could lower insulin resistance during pregnancy and consecutively benefit neonatal body composition.

ACKNOWLEDGEMENTS

We would like to thank all participants for their time on participating in this study. In the United Kingdom, the DALI team acknowledge the support received from the NIHR Clinical Research Network: Eastern, especially the local diabetes clinical and research teams based in Cambridge.

ORCID

Rodrigo A. Lima https://orcid.org/0000-0002-7778-2616

REFERENCES


